|1.||Criado, P R: 1 article (11/2002)|
|2.||de Mello, J F: 1 article (11/2002)|
|3.||Galvão, C: 1 article (11/2002)|
|4.||Fernandes, M F M: 1 article (11/2002)|
|5.||Criado, R F J: 1 article (11/2002)|
|6.||Valente, N Y S: 1 article (11/2002)|
|1.||Asthma (Bronchial Asthma)
01/01/1994 - "Severe bronchial asthma improved on bamifylline. "
02/28/1986 - "[Clinical experience with bamifylline in children with asthmatic bronchitis or bronchial asthma]."
11/01/1967 - "[Treatment of asthma and chronic respiratory insufficiency by AC 3810 (trentadil)]."
01/01/1990 - "Two homogeneous groups of 8 patients suffering from bronchial asthma or chronic obstructive bronchial pneumonia were treated with slow release theophylline anhydride or bamiphylline respectively, both products being given orally twice a day. "
05/01/1982 - "Protective and curative effects of parenterally administered bamifylline and theophylline on bronchospasm induced by standardized house dust inhalation were studied in two series of eight patients with allergic asthma to house dust. "
|2.||Anaphylaxis (Anaphylactic Shock)
01/01/1997 - "In addition, bamiphylline had little effect on anginal pain, suggesting that this cannot be mediated exclusively by A1-receptor stimulation in these patients."
06/01/1996 - "In bamiphylline-treated patients, the mean ST segment shift and the severity of cardiac pain during the second inflation were similar to those during the first inflation (14 +/- 15 vs 16 +/- 16 mm, ns and 31 +/- 28 vs 31 +/- 29, ns, respectively). "
01/01/1995 - "Bamiphylline reduces adenosine-induced muscular and cardiac pain but does not affect adenosine-induced coronary vasodilation. "
01/01/1995 - "Bamiphylline prolonged the time to pain onset caused by intracoronary adenosine infusion from 519 +/- 128 to 603 +/- 146 s (p < 0.01) and reduced pain severity from 58 to 28 mm (p < 0.02). "
01/01/1995 - "Bamiphylline prolonged the time to pain onset caused by the intrailiac adenosine infusion from 444 +/- 96 to 749 +/- 120 s (p < 0.001) and reduced pain severity from 45 to 24 mm (p < 0.01). "
01/01/1995 - "A double-blind study versus placebo was performed to assess the effect of bamiphylline, a new xanthylic derivative, on tracheobronchial mucus clearance (TBMC) in smokers with simple chronic bronchitis and impaired mucus clearance as compared to normal controls. "
01/01/1995 - "Effect of bamiphylline on tracheobronchial mucus clearance in subjects with smokers' simple chronic bronchitis."
11/01/1965 - "Bamifylline hydrochloride, a new xanthine derivative, in chronic bronchitis."
|5.||Chronic Obstructive Pulmonary Disease (COPD)
03/01/1991 - "Therefore we believe that bamiphylline must be considered an effective therapeutic tool for COPD therapy."
03/01/1991 - "We studied the clinical and instrumental modifications of 20 patients (mean age: 67.95 +/- 1.23 years; 13 males, 7 females) suffering from COPD (less than 65% theoretical FEV1), during treatment with bamiphylline. "
03/01/1991 - "[Therapeutic effectiveness of bamifylline in elderly patients with COPD]."
01/01/1991 - "From these data we conclude that in patients with COPD, clinical manifestations, probably associated with inspiratory muscle overloading (decrease in muscle strength, RSB, increase in respiratory neural drive, and derangement in neuromuscular coupling) may benefit from a short-term treatment with bamiphylline."
|2.||Purinergic P1 Receptors (Adenosine Receptor)
|5.||Purinergic P1 Receptor Antagonists
|7.||Dust (House Dust)
|9.||8- (4- ((2- aminoethyl)aminocarbonylmethyloxy)phenyl)- 1,3- dipropylxanthine
|3.||Drug Therapy (Chemotherapy)